Clinical Trial Update: MPOD in Macular Teleangiectasia Following Supplementation of Lutein and Zeaxanthin

View source ↗

Summary

This clinical trial update assesses changes in macular pigment density (MPOD) after supplementation with lutein and zeaxanthin in macular telangiectasia type 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Telangiectasia Type

Drugs mentioned

• Lutein (lutein)
• Zeaxanthin (Zeaxanthin)

Snippet

Sponsor: The Lowy Medical Research Institute Limited | Conditions: Macular Teleangiectasia, Macular Pigment | Status: UNKNOWN